We are excited to announce that Pharmecons Easy Access Ltd. has entered into a collaboration with Exzellia Pharma Ltd. and Dr. Stalo Charalambous. Through this partnership, Pharmecons will enhance its footprint and activities in Cyprus and Malta, leveraging Dr. Charalambous’ extensive knowledge and expertise in the healthcare landscapes of these regions, along with her extensive experience in the multinational pharmaceutical industry.
Continue reading
The European Health Data Space (‘EHDS’) is the first proposal of such domain-specific common European data spaces. It will address health-specific challenges to electronic health data access and sharing, is one of the priorities of the European Commission in the area of health 2 and will be an integral part of building a European Health Union.
Continue reading
The Regulation (EU) 2021/2282 on health technology assessment (HTAR) contributes to improving the availability for EU patients of innovative technologies in the area of health, such as medicines and certain medical devices. It ensures an efficient use of resources and strengthens the quality of HTA across the Union.
It provides a transparent and inclusive framework by establishing a Coordination Group of HTA national or regional authorities, a stakeholder network and by laying down rules on the involvement in joint clinical assessments and joint scientific con-sultations of patients, clinical experts and other relevant experts.
The HTAR will also reduce duplication of efforts for national HTA authorities and industry, facilitate business predictability and ensure the long-term sustainability of EU HTA cooperation.
HosmartAI EU Project, an amazing and ambitious journey for Pharmecons Easy Access who will perform the economic evaluation of the AI technologies has just started!
On the last 9-10 February, took place the kick-off meeting of the new project HosmartAI –
“Hospital Smart development based on AI”. The project is funded by €10 million under European
Union’s Horizon 2020 research and innovation programme (Grant Agreement No 101016834).